The domestic approval of Vabysmo, the first and only dual-specific antibody biological drug related to eye diseases developed by Roche, is imminent. Vabysmo has been approved as an nAMD treatment and DME treatment in more than 40 countries around the world, including the United States, Japan, the United Kingdom, and the European Union, and was approved by the U.S. FDA in January last year. According to industries on the 5th, the Ministry of Food and Drug Safety recently completed a safety and effectiveness review of Vabysmo. If the review is completed without any problems, product approval is expected to take place soon. Vabysmo is the first and only ophthalmic injection approved by the FDA for nAMD and DME simultaneo